Gland Pharma Ltd - 543245 - Related Party Transactions For The Half Year Ended 30Th September 2022
Related Party Transactions for the half year ended 30th September 202204-11-2022
04-11-2022
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Earnings call Transcript for Q2FY2302-11-2022
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Schedule of the Investor meeting01-11-2022
Gland Pharma stock lose 24% of its value in 3 days. What's spooking investors?
Gland Pharma said revenue from its core markets of the US, Europe, Canada and Australia grew by 3 per cent to Rs 747.5 crore in the second quarter, as against Rs 722.5 crore in the corresponding period last fiscal31-10-2022
Buy Gland Pharma; target of Rs 2260: Sharekhan
Sharekhan is bullish on Gland Pharma has recommended buy rating on the stock with a target price of Rs 2260 in its research report dated October 27, 2022.28-10-2022
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Schedule of Investor meetings28-10-2022
Uncertainty on revenue growth, margin outlook hits Gland Pharma stock
The injectable manufacturing company expects the margin pressure to persist due to cost pressures and negative operating leverage.27-10-2022
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Publication pertaining to Unaudited Financial Results of Q2FY2327-10-2022
Q2FY23 Quarterly Result Announced for Gland Pharma Ltd.
Gland Pharma announced Q2FY23 results: Revenue from operations during the quarter has improved by 22% as compared to first quarter of the current year but declined by 3% as compared to corresponding quarter of the previous year. Revenue from operations for the six months ended September 30, 2022, declined by 15% as compared to the corresponding period of previous year due substantial business impact in first quarter of current financial year and higher base due to COVID related products sales in last year. Gross Margin of the Company remained stable in first half of the year as compared to same period of previous financial year but reduced sequentially largely due to change in Geography mix and product mix. The Company has generated Rs 3,956 million of cash flow from operations during first half of FY23. As of September 2022, the company had total Rs 38,200 million of Cash and Bank balances. Commenting on the results, Mr. Srinivas Sadu, MD & CEO of Gland Pharma said “We closed this quarter Q2 FY23, with a revenue of Rs 10,444 million and a PAT of Rs 2,412 million. We continue to make investments in R&D; and were able to complete 6 ANDA filings during this quarter. Although we have seen increased competition in our new products, we remain confident of our launch pipeline that will ensure sustainable growth. We are seeing positive momentum in our Biologics/Biosimilar CDMO business.” Result PDF27-10-2022
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Audio recording of Earnings Call for the quarter and half year ended September 30, 202226-10-2022